Smith-Lemli-Opitz syndrome produced in rats with AY 9944 treated by intravenous injection of lipoprotein cholesterol.
A limitation to treating Smith-Lemli-Opitz infants by giving dietary cholesterol is their impaired ability to absorb cholesterol due to a deficiency of bile acids. Since intravenously administered lipoprotein cholesterol should not require bile acids for uptake into tissues, we tested the effects of this form of cholesterol on tissue cholesterol and 7-dehydrocholesterol levels in an animal model of SLO, created by feeding rats 0.02% AY 9944. Intravenous administration of 15 mg of bovine cholesterol supertrate twice daily increased serum cholesterol levels from 11 to over 250 mg/dl. This treatment increased liver cholesterol levels from 309 to over 900 micrograms/g and lowered hepatic 7-dehydrocholesterol levels from 1546 to 909 micrograms/g. A combination of iv cholesterol and 2% dietary cholesterol was most effective as it raised hepatic cholesterol levels to 1950 micrograms/g, which is 50% above normal. 7-Dehydrocholesterol levels were decreased to 760 micrograms/g. Similar responses were seen for heart, lung, kidney, and testes. Brain sterol levels were not significantly affected. AY 9944 caused a modest increase in hepatic HMG-CoA reductase activity. Administration of dietary cholesterol together with iv cholesterol lowered hepatic HMG-CoA reductase activity to barely detectable levels. The data indicate that the combination of iv and dietary cholesterol was most effective in raising cholesterol levels, lowering 7-dehydrocholesterol levels, and inhibiting de novo cholesterol biosynthesis.
Chambers
C M
CM
Department of Biochemistry, College of Medicine, University of South Florida, Tampa 33612, USA.
McLean
M P
MP
Ness
G C
GC
D000818:Animals; D000924:Anticholesteremic Agents; D002784:Cholesterol / Q000378:metabolism / Q000627:therapeutic use*; D002791:Cholesterol, Dietary / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003684:Dehydrocholesterols / Q000378:metabolism; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors; D007275:Injections, Intravenous; D008074:Lipoproteins / Q000627:therapeutic use*; D008297:Male; D010088:Oxidoreductases / Q000037:antagonists & inhibitors; D044925:Oxidoreductases Acting on CH-CH Group Donors; D051381:Rats; D017207:Rats, Sprague-Dawley; D019082:Smith-Lemli-Opitz Syndrome / Q000139:chemically induced / Q000178:diet therapy / Q000188:drug therapy*; D001371:trans-1,4-Bis(2-chlorobenzaminomethyl)cyclohexane Dihydrochloride
D000924:Anticholesteremic Agents; D002791:Cholesterol, Dietary; D003684:Dehydrocholesterols; D004791:Enzyme Inhibitors; D008074:Lipoproteins; C030104:lipoprotein cholesterol; D001371:trans-1,4-Bis(2-chlorobenzaminomethyl)cyclohexane Dihydrochloride; D002784:Cholesterol; C016705:7-dehydrocholesterol; D010088:Oxidoreductases; D044925:Oxidoreductases Acting on CH-CH Group Donors; C019995:7-dehydrocholesterol reductase